In cancers expressing WT p53 treated by kinesin-5 inhibitors, down-regulation of survivin is likely to be a preferred strategy for treatment, inducing mitotic slippage and apoptotic death by the tetraploidy checkpoint. This evidence concerns the gene BIRC5 and cancer.